Perflutren lipid
Phase 3Small molecule
Perflutren lipid is one of 49 small molecule programs targeting Spinal Cord Injury. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
62 competitors in Spinal Cord Injury
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Levitra
BayerApproved
Keppra
UCBApproved
Cialis
Eli LillyApproved
Ozempic
Novo NordiskApproved
Elavil
AstraZenecaApproved
Calciferol
Jazz PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lioresal
NovartisApproved
Prolia
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Perflutren lipid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Washington